Signal transduction components, incuding the Ras superfamily of low molecular weight GTP-binding proteins and the y subunits of heterotrimeric G proteins, are reversibly carboxyl methylated at C-terminal prenylcysteine residues. We have previously shown that the prenylcysteine analog N-acetyl-S-tans,trans-farnesyl-L-cysteine (AFC) inhibits carboxyl methylation of these proteins in human platelets. Here we show that concentrations of AFC that inhibit Ras carboxyl methylation also block responses to agonists such as ADP, collagen, arachidonic acid, U46619 (a stable analog of prostaglandin H2), thrombin, and guanoine 5'-[y-thioltriphosphate. AFC does not inhibit aggregation induced by effectors such as ionomycin, phorbol 12,13-dibutyrate, and bacterial phospholipase C that bypass G proteins to activate platelets at the level of cytosolic Ca2+ concentration and protein kinase C. These findings indicate that AFC inhibits agonist-receptor-mediated signal transduction in human platelets.
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The finding that Ras proteins and the heterotrimeric G proteins are methylated at the carboxyl group of the C terminus has raised the possibility that this type of reversible covalent modification may play a role in signal transduction (1, 2) . These GTP-binding proteins function to relay information from membrane receptors to control the cytoplasmic levels of second messengers, such as cAMP, cytosolic Ca2W, and diacylglycerol (DAG) (3, 4) , that act in turn to regulate protein kinases. Ras proteins and the y subunits of G proteins are initially synthesized with a characteristic C-terminal sequence, CXXX (a cysteine followed by three, generally aliphatic, residues) (2, 5) . CXXX sequences provide a recognition site for cytosolic prenyltransferase enzymes, which catalyze the attachment of farnesyl or geranylgeranyl polyisoprenoid groups in thioether linkage to the cysteine (2, 6) . The three residues distal to the cysteine in prenylated CXXX sequences are removed by membrane-associated protease activities (7) , and the exposed prenylcysteine a-carboxylate undergoes methylesterificationbyamembrane-bound S-adenosylmethionine:prenylcysteine methyltransferase (8, 9) .
Results with inhibitors ofpolyisoprenoid synthesis, such as compactin and mevinolin (lovastatin), indicate that prenylation is essential for the function of Ras proteins and 'y subunits ofthe heterotrimeric G proteins (10) (11) (12) (13) . Prenylation is required for all subsequent steps in CXXX processing (13, 14) , and without prenylation, these proteins cannot localize to their sites of action at the plasma membrane (15) (16) (17) . Classical heterotrimeric G proteins as well as low molecular weight G proteins such as rapla, rapib, rap2, and rap2b are present in human platelets (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . To specifically investigate the role of carboxyl methylation in G-protein-dependent signal transduction, we have examined the effects of a prenylcysteine methyltransferase inhibitor, N-acetyl-Strans,trans-farnesyl-L-cysteine (AFC), on agonist-receptormediated signal transduction in human platelets. AFC has previously been shown to be an inhibitor of protein carboxyl methylation in platelets (28) and other cell types (9, 29, 30 ). Here we show that AFC but not N-acetyl-S-trans,transgeranyl-L-cysteine (AGC), which is a poor inhibitor ofprotein methylation (9) Collection of Blood and Preparation of Washed Platelet Suspensions. Blood was collected from normal human volunteers who reported to be without medication for at least 10 days. Acid/citrate/dextrose solution (32) was used as an anticoagulant in a ratio of 1:6 (vol/vol). Citrated blood was centrifuged at 120 x g for 15 min at room temperature. The supernatant, platelet-rich plasma, was centrifuged at 1100 x g for 15 min and the platelet pellet was resuspended in modified Tyrode's solution without calcium, pH 6.5 (33) . Two percent EGTA was added (1:9, vol/vol) to platelet suspensions just before centrifugation at 1100 x g for 10 min, and this washing procedure was repeated three times. Platelets were finally resuspended in modified Tyrode's solution, tTo whom reprint requests should be addressed.
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for aggregation studies and to 1. induce platelet aggregation by interacting with specific receptors, whereas arachidonic acid induces platelet aggregation by being converted into prostaglandins, specifically into thromboxane A2 (TXA2) (38) (39) (40) (41) (42) (43) . AFC (1-10 ,uM) inhibited platelet aggregation induced by ADP, collagen, arachidonic acid, and U46619 ( Fig. 1) . Slightly greater concentrations of AFC (10-50 ,uM) were needed to inhibit thrombin-induced platelet aggregation (Fig. 1) . AFC also inhibited both thrombin-and U46619-induced serotonin secretion (Fig. 2) (Fig. 3) . AFC inhibited GTP[yS]-induced platelet aggregation in a concentration-dependent manner (Fig. 3) . [Ca2+]i induced by low (0.1 gM) (Fig. 6A) as well as high (1.0 uM) (Fig. 6B) concentrations of U46619. Slightly higher concentrations ofAFC were required to inhibit the thrombininduced increase in platelet [Ca2+]j (Fig. 6C) . However, AFC did not inhibit ionomycin-induced increase in platelet [Ca2+] from extracellular (in the presence of 2 mM calcium in the medium; Fig. 6D ) or intracellular (in the presence of 1 mM EGTA in the medium; Fig. 6E ) sources.
DISCUSSION
Agonists stimulate platelets by various mechanisms. Thrombin and U46619 interact with specific receptors that are coupled by G proteins to signal-transduction pathways. These lead to the hydrolysis of membrane phospholipids and to the generation of inositol 1,4,5-trisphosphate (IP3), DAG, and TXA2, with subsequent mobilization of cytosolic Ca2+ and activation ofprotein kinase C (38-41). On the other hand, agents such as PDBu, PLC, and ionomycin bypass receptors and G proteins. PLC induces hydrolysis of membrane phospholipids to produce DAG, which in turn activates protein kinase C (45) (46) (47) . PDBu directly activates protein kinase C. lonomycin directly mobilizes Ca2+ from intra-and extracellular sources. If AFC affects platelet activation by inhibiting the methylation of y subunits of G proteins or low molecular weight GTP-binding proteins, such as rapi, it would be expected to inhibit platelet activation by agonists such as thrombin or U46619, but not agents such as PDBu, PLC, or ionomycin.
AFC completely inhibited platelet aggregation induced by thrombin and collagen (Fig. 1) . Thrombin and collagen induce platelet aggregation by multiple mechanisms, including secretion of ADP and production of TXA2, 1P3, and DAG (42) . ADP induces a characteristic biphasic aggregation response in human platelets. The secondary phase of ADP-induced platelet aggregation, which is mediated by prostaglandins synthesized during primary aggregation, was inhibited by AFC (Fig. 1) . AFC also inhibited arachidonic acid-induced platelet aggregation. Arachidonic acid induces platelet aggregation by being converted into prostaglandins (43) . Our results suggest that AFC inhibits platelet aggregation by inhibiting the synthesis or the action of prostaglandins, or both. U46619, a stable analog of prostaglandin H2, induces platelet aggregation by directly interacting with TXA2 receptors (38) . AFC inhibited U46619-induced aggregation and serotonin secretion in the presence or absence of aspirin (0. Inhibition of receptor-dependent G-protein activation by thrombin, U46619, or TXA2 would inhibit stimulation of inositol phospholipid-specific PLC and consequently the production of IP3 and DAG. IP3 induces platelet aggregation by mobilizing Ca2+ from the dense tubular system. AFC inhibited thrombin-and U46619-induced, but not ionomycininduced, increases in [Ca2+]J (Fig. 6) . Thus, AFC inhibits agonist-receptor-mediated, but not direct, Ca2+ mobilization.
A number of antiplatelet agents such as prostaglandin E1, prostacyclin, and methylxanthines inhibit platelet aggregation by increasing platelet cAMP levels (41, (48) (49) (50) . Increase in cAMP inhibits platelet activation mediated by diverse stimuli including thrombin and TXA2 as well as PDBu and PLC. The possibility that AFC may also be inhibiting platelet Proc. Natl. Acad. Sci. USA 90 (1993) 3-deazaadenosine and L-homocysteine thiolactone increase platelet cAMP and inhibit platelet aggregation induced by receptor-dependent (U46619) as well as receptor-independent (PLC) mechanisms (50) . Thus the antiplatelet actions of 3-deazaadenosine and L-homocysteine thiolactone, but not those of AFC, may be attributable to an increase in cAMP level. DAG induces aggregation by stimulating a protein kinase C-dependent phosphorylation of a 47-kDa protein (40) . AFC does not interfere with this process, since it did not inhibit aggregation in response to PDBu (Fig. 5) , an agent known to activate protein kinase C by mimicking the action of DAG (46) . In addition, AFC did not inhibit PLC-stimulated aggregation (Fig. 5) , a process that depends on the in situ generation of DAG (47) . AFC also did not inhibit platelet aggregation induced by ionomycin (Fig. 5) . These results support the conclusion that AFC inhibits platelet activation by blocking agonist-receptor-mediated signal-transduction pathways that lead to the generation of second messengers, such as IP3, Ca2+, and DAG.
The findings that AFC inhibited only agonist-receptorinduced platelet activation suggests that it may be blocking the G-protein-mediated signal transduction. This possibility is further supported by the fact that AFC also inhibited GTP[(yS]-induced platelet aggregation (Fig. 3) . Finally, it is tempting to speculate that GTP['yS]-dependent carboxyl methylation of rap proteins (28) may be involved in agonistreceptor-mediated signal transduction and that AFC inhibits agonist-receptor-mediated signal transduction in human platelets by blocking methylation of these proteins. A possible link between inhibition of protein methylation and inhibition of platelet aggregation is also supported by observations that AFC, which is a potent inhibitor of protein methylation, but not AGC, which is a poor inhibitor of protein methylation, inhibits agonist-receptor-mediated platelet responses.
